Vijaya Pattabiraman
Co-founder & Chief Technology Officer Bright Peak Therapeutics
Seminars
Monday 3rd November 2025
Spotlighting the Versatility & Emerging Therapeutic Profile of BPT567 – A Novel PD1-IL18 Based Immunoconjugate
2:00 pm
- Detailing Bright Peak protein engineering and protein conjugation to construct BPT567 and other antibody-protein conjugates
- Showcasing preclinical activity of immunoconjugate BPT567 with IL-18 payload
- Reviewing plans for ongoing Phase 1/2a in-human study and highlighting the need for novel ADC payload innovation
